Dr. Brian D. Modena, M.D., MSC
Allergy & Immunology (Allergy & Immunology Physician)
9850 Genesee Ave Ste 710
La Jolla, CA 92037
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- West Virginia University School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 199
Licensed in California since 2008, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2006Medical school: West Virginia University School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
CA license A103242 (first issued 2008; current) -
Allergy & Immunology (Internal Medicine) Physician
CA license A103242 (first issued 2008; current) -
Internal Medicine Physician
CA license A103242 (first issued 2008; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Scripps Memorial Hospital La Jolla La Jolla, CA
- Sharp Coronado Hospital and Hlthcr Ctr Coronado, CA
Medical groups
- Modena Allergy and Asthma Inc. (26 clinicians)
- Modena Allergy and Asthma II Inc. (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 199
- Services billed
- 56,198
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, tezepelumab-ekko, 1 mg | 14,910 | 13 |
| Injection, mepolizumab, 1 mg | 6,900 | 12 |
| Injection, omalizumab, 5 mg | 4,440 | 12 |
| Test for allergy using allergenic extract | 2,964 | 44 |
| Test for allergy using skin patch | 1,440 | 18 |
| Professional service for preparation and provision of 1 or more antigens | 651 | 24 |
| Injection of drug or substance under skin or into muscle | 349 | 46 |
| Professional service for multiple injections of allergen | 331 | 32 |
| Established patient office or other outpatient visit, 30-39 minutes | 324 | 118 |
| Test to measure expiratory airflow and volume | 138 | 58 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ipratropium Bromide Other prescribers in La Jolla, CA | 158 |
| Azelastine Hcl Other prescribers in La Jolla, CA | 90 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in La Jolla, CA | 37 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in La Jolla, CA | 35 |
| Montelukast Sodium Other prescribers in La Jolla, CA | 34 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in La Jolla, CA | 27 |
| Breyna (budesonide/formoterol fumarate) Other prescribers in La Jolla, CA | 27 |
| Fluticasone Propionate Other prescribers in La Jolla, CA | 18 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in La Jolla, CA | 18 |
| Prednisone Other prescribers in La Jolla, CA | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 26 companies reported 174 payments worth $21,125 in total to this clinician.
| Sanofi-aventis U.S. LLC | $9,598 |
|---|---|
| Genzyme Corporation | $3,893 |
| Blueprint Medicines Corporation | $2,678 |
| AstraZeneca Pharmaceuticals LP | $1,507 |
| GlaxoSmithKline, LLC. | $892 |
| Amgen Inc. | $427 |
| Novartis Pharmaceuticals Corporation | $415 |
| Regeneron Healthcare Solutions, Inc. | $341 |
| Compensation for services other than consulting (speaking, faculty) | $9,522 |
|---|---|
| Consulting Fee | $4,494 |
| Food and Beverage | $4,464 |
| Honoraria | $2,551 |
| Travel and Lodging | $76.00 |
| Education | $17.38 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi-aventis U.S. LLC Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $9,522 |
| Genzyme Corporation Feb 27, 2025 | Consulting Fee | $3,420 |
| Blueprint Medicines Corporation Mar 14, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $2,551 |
| AstraZeneca Pharmaceuticals LP Mar 20, 2025 | Consulting Fee FASENRA · Respiratory | $1,074 |
| Sanofi-aventis U.S. LLC Apr 3, 2025 | Travel and Lodging travel to Florida, MI | $76.00 |
| Insmed, Inc. Sep 23, 2025 | Education Brinsupri; Brinsupri · Respiratory · in-kind | $17.38 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 7 companies. The companies reported $737,588 in research payments for these studies, mostly to the institutions running them.
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
Sanofi US Services Inc. · Completed · NCT06691113 - A prospective, real-world, interventional study to evaluate the effect
GlaxoSmithKline, LLC. - Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi US Services Inc. · Recruiting · NCT05263206 - A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
Sanofi US Services Inc. · Completed · NCT06454240 - (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Sanofi US Services Inc. · Recruiting · NCT04910685 - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983 - Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
Sanofi US Services Inc. · Active, not recruiting · NCT06914908 - Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06572228 - A Multicentre,Randomised,Double Blind,Parallel Group,Placebo Controlled,52 week,Phase 3,Efficacy and Safety Study of Tezepelumab in 5 to 12 Year Old Children with Severe Uncontrolled Asthma HORIZON
AstraZeneca Pharmaceuticals LP - BLU-808-1201
Blueprint Medicines Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.